Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (121-130 of 219) with videos related to

Pageof 22
Sort By:
Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Kim A Papp, Richard G Langley, Mark Lebwohl, et al.
Dermatology and Therapy|August 17, 2024
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical TrialsKenneth B Gordon, Andrew Blauvelt, Hervé Bachelez, et al.
JAMA Dermatology|December 20, 2023
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical TrialKim A Papp, Kenneth Gordon, Bruce Strober, et al.
Dermatology and Therapy|December 23, 2021
Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based MethodologyKim A Papp, Melinda J Gooderham, Charles W Lynde, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2024
Considerations for defining and diagnosing generalized pustular psoriasisVimal H Prajapati, Charles W Lynde, Melinda J Gooderham, et al.
The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Adalimumab in Plaque PsoriasisRichard B Warren, Andrew Blauvelt, Jerry Bagel, et al.
BMC Dermatology|June 23, 2019
Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin AmericaKim A Papp, Melinda Gooderham, Jennifer Beecker, et al.
Journal of the American Academy of Dermatology|October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsKenneth B Gordon, Kim A Papp, Richard G Langley, et al.
JAMA Dermatology|April 9, 2020
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical TrialAndrew Blauvelt, Craig L Leonardi, Melinda Gooderham, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2022
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitisAndrew Blauvelt, Leon Kircik, Kim A Papp, et al.
Pageof 22

Showing results (121-130 of 219) with videos related to

Sort By:
Pageof 22
Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Kim A Papp, Richard G Langley, Mark Lebwohl, et al.
Dermatology and Therapy|August 17, 2024
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical TrialsKenneth B Gordon, Andrew Blauvelt, Hervé Bachelez, et al.
JAMA Dermatology|December 20, 2023
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical TrialKim A Papp, Kenneth Gordon, Bruce Strober, et al.
Dermatology and Therapy|December 23, 2021
Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based MethodologyKim A Papp, Melinda J Gooderham, Charles W Lynde, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2024
Considerations for defining and diagnosing generalized pustular psoriasisVimal H Prajapati, Charles W Lynde, Melinda J Gooderham, et al.
The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Adalimumab in Plaque PsoriasisRichard B Warren, Andrew Blauvelt, Jerry Bagel, et al.
BMC Dermatology|June 23, 2019
Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin AmericaKim A Papp, Melinda Gooderham, Jennifer Beecker, et al.
Journal of the American Academy of Dermatology|October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsKenneth B Gordon, Kim A Papp, Richard G Langley, et al.
JAMA Dermatology|April 9, 2020
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical TrialAndrew Blauvelt, Craig L Leonardi, Melinda Gooderham, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2022
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitisAndrew Blauvelt, Leon Kircik, Kim A Papp, et al.
Pageof 22